Physician profile
David Douglas Shepard
NPI 1053588731
$80,777.93
in general payments reported to CMS, 2019-2025
67 companies · $4,760 in 2025
The $4,760 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $12K · 2021: $7,720 · 2022: $492 · 2023: $12K · 2024: $8,789 · 2025: $4,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Long Term Medical Supply Or Device Loan: $2,164 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,214.44 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,625.00 |
| Long Term Medical Supply Or Device Loan | $2,163.62 |
| Education | $310.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $39,917.72 | 2019-2024 | Nplate, Kyprolis, Xgeva |
| Coherus Oncology, INC. | $14,097.86 | 2020-2025 | Udenyca, Loqtorzi |
| Astrazeneca Pharmaceuticals LP | $10,376.10 | 2019-2025 | Lynparza, Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $2,789.18 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,277.12 | 2019-2024 | Gilotrif |
| Rigel Pharmaceuticals, INC. | $1,093.32 | 2020-2025 | Rezlidhia, Tavalisse, Gavreto |
| Genentech USA, INC. | $949.74 | 2019-2025 | Tecentriq, Polivy, Alecensa |
| Exelixis INC. | $692.27 | 2022-2025 | Cabometyx |
| Daiichi Sankyo INC. | $609.03 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Merck Sharp & Dohme LLC | $575.34 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $539.99 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $489.58 | 2023-2025 | Libtayo, Lynozyfic |
| E.R. Squibb & Sons, L.L.C. | $465.21 | 2020-2025 | Opdivo, Breyanzi, Opdualag |
| Janssen Biotech, INC. | $447.81 | 2022-2025 | Darzalex, Erleada, Talvey |
| Sobi, INC | $419.61 | 2022-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $402.91 | 2023-2025 | |
| Genzyme Corporation | $360.46 | 2023-2025 | |
| Abbvie INC. | $354.80 | 2024-2025 | |
| Celgene Corporation | $313.79 | 2022-2025 | Reblozyl, Opdualag, Pomalyst |
| Glaxosmithkline, LLC. | $277.60 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $269.14 | 2023-2025 | Alunbrig, Iclusig, Fruzaqla |
| Eisai INC. | $226.94 | 2022-2024 | |
| Genmab U.S., INC. | $214.79 | 2023-2025 | Epkinly |
| Incyte Corporation | $214.60 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Stemline Therapeutics INC. | $206.36 | 2023-2025 | Orserdu |
| Seagen INC. | $203.94 | 2022-2023 | Tukysa, Adcetris, Padcev |
| Foundation Medicine, INC. | $192.77 | 2022-2023 | Foundationone Cdx |
| Gilead Sciences, INC. | $165.13 | 2021-2025 | Trodelvy |
| Verity Pharmaceuticals INC. | $148.48 | 2023-2025 | Trelstar, Tlando |
| Secura Bio, INC. | $142.95 | 2023 | Copiktra |
| Puma Biotechnology, INC. | $142.68 | 2022-2025 | Nerlynx |
| Pharmacyclics LLC, An Abbvie Company | $137.48 | 2023 | Imbruvica |
| Galt Pharmaceuticals, LLC | $133.97 | 2023 | Orphengesic Forte |
| Lilly USA, LLC | $127.83 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Jazz Pharmaceuticals INC. | $119.45 | 2024-2025 | |
| Adc Therapeutics America, INC. | $107.24 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $99.45 | 2023-2025 | Xpovio |
| Emd Serono, INC. | $95.99 | 2024-2025 | |
| Zimmer Biomet Holdings, INC. | $91.76 | 2021 | |
| Deciphera Pharmaceuticals INC. | $80.50 | 2023-2025 | Qinlock, Romvimza |
| Tersera Therapeutics LLC | $79.96 | 2023-2025 | Zoladex |
| Sun Pharmaceutical Industries INC. | $72.45 | 2024-2025 | |
| Beone Medicines USA, INC. | $68.81 | 2025 | Tevimbra, Brukinsa |
| Mirati Therapeutics, INC. | $62.08 | 2023 | Krazati |
| Acrotech Biopharma INC. | $60.93 | 2024-2025 | Beleodaq |
| Aveo Pharmaceuticals, INC. | $57.02 | 2024-2025 | |
| Blueprint Medicines Corporation | $56.93 | 2023-2025 | Ayvakit |
| Caris Mpi, INC. | $56.22 | 2025 | Mi Cancer Seek |
| Pharmaessentia USA Corporation | $56.05 | 2024-2025 | Besremi |
| Astellas Pharma US INC | $54.56 | 2024 | Xtandi, Vyloy |
| Agios Pharmaceuticals, INC. | $52.40 | 2023-2025 | Pyrukynd |
| Tempus Ai, INC | $48.33 | 2025 | Xt Cdx |
| Array Biopharma INC | $46.84 | 2023-2024 | Braftovi, Lorbrena, Mektovi |
| Fennec Pharmaceuticals, INC. | $42.76 | 2024-2025 | Pedmark, Fyarro |
| Alexion Pharmaceuticals, INC. | $41.39 | 2023-2024 | Ultomiris |
| Legend Biotech USA INC. | $39.60 | 2025 | Carvykti |
| Beigene USA, INC. | $39.43 | 2022-2023 | Brukinsa |
| Dendreon Pharmaceuticals LLC | $35.23 | 2023-2024 | Provenge |
| Geron Corporation | $32.45 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $30.83 | 2024-2025 | Monoferric, Cosela |
| Ipsen Biopharmaceuticals, INC | $30.44 | 2025 | Onivyde |
| Springworks Therapeutics, INC. | $29.44 | 2025 | Gomekli |
| Myriad Genetic Laboratories, INC. | $24.62 | 2024 | Myrisk |
| G1 Therapeutics, INC. | $24.07 | 2023 | Cosela |
| Recordati_rare_diseases_inc. | $22.11 | 2024 | Sylvant |
| Apellis Pharmaceuticals, INC. | $21.16 | 2025 | Empaveli |
| Immunogen, INC. | $20.93 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shepard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.